Canna~Fangled Abstracts

Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure

By November 17, 2020 No Comments
Review

doi: 10.1155/2020/4587024. eCollection 2020.

Affiliations 

Abstract

A large number of cannabinoids have been discovered that could play a role in mitigating cardiac affections. However, none of them has been as widely studied as cannabidiol (CBD), most likely because, individually, the others offer only partial effects or can activate potential harmful pathways. In this regard, CBD has proven to be of great value as a cardioprotective agent since it is a potent antioxidant and anti-inflammatory molecule. Thus, we conducted a review to condensate the currently available knowledge on CBD as a therapy for different experimental models of cardiomyopathies and heart failure to detect the molecular pathways involved in cardiac protection. CBD therapy can greatly limit the production of oxygen/nitrogen reactive species, thereby limiting cellular damage, protecting mitochondria, avoiding caspase activation, and regulating ionic homeostasis. Hence, it can affect myocardial contraction by restricting the activation of inflammatory pathways and cytokine secretion, lowering tissular infiltration by immune cells, and reducing the area of infarct and fibrosis formation. These effects are mediated by the activation or inhibition of different receptors and target molecules of the endocannabinoid system. In the final part of this review, we explore the current state of CBD in clinical trials as a treatment for cardiovascular diseases and provide evidence of its potential benefits in humans.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 2

Similar articles

 See all similar articles

References

    1. Campos A. C., Moreira F. A., Gomes F. V., del Bel E. A., Guimarães F. S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences. 2012;367(1607):3364–3378. doi: 10.1098/rstb.2011.0389. – DOI – PMC – PubMed
    1. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988;34(5):605–613. – PubMed
    1. Horváth B., Mukhopadhyay P., Haskó G., Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. The American Journal of Pathology. 2012;180(2):432–442. doi: 10.1016/j.ajpath.2011.11.003. – DOI – PMC – PubMed
    1. Shayesteh M. R. H., Haghi-Aminjan H., Mousavi M. J., Momtaz S., Abdollahi M. The protective mechanism of cannabidiol in cardiac injury: a systematic review of non-clinical studies. Current Pharmaceutical Design. 2019;25(22):2499–2507. doi: 10.2174/2210327909666190710103103. – DOI – PubMed
    1. Lee W.-S., Erdelyi K., Matyas C., et al. Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Molecular Medicine. 2016;22(1):136–146. doi: 10.2119/molmed.2016.00007. – DOI – PMC – PubMed

Publication types

Leave a Reply

en English